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Short report Management of stage one and two-E gastric large 
B-cell lymphoma: chemotherapy alone or surgery 
followed by chemotherapy?
Yassir Sbitti*1,2, Nabil Ismaili*2, Youssef Bensouda2, Habiba Kadiri3, Mohammed Ichou1 and Hassan Errihani2
Abstract
Management of localized primary gastric B lymphoma (PGL) remains controversial. The aim of this study is to compare 
two treatments: chemotherapy alone and surgery plus chemotherapy.
Materials: Records of all patients with a diagnosis of gastric lymphoma and which were treated in the National 
Institute of Oncology, between 1999 and 2006, were reviewed and patients fulfilling the following criteria were 
included in this study: histologically proven large-cell B lymphoma of the stomach; complete clinical information stage 
I/II disease according to the Musshoff staging; patients who received surgery followed by chemotherapy (group I) or 
chemotherapy alone (group II).
Results: This study included 82 patients who were treated for cancer in our Institute. All clinical and pathological 
features were similar between the two groups, except that patients of group-I had significantly more stage II disease (P 
= 0.023) than that of group II. Among the 52 patients who could be evaluated for response to chemotherapy, there 
were 45 who had complete response to treatment, 3 had partial response to the treatment and 4 had progressive 
disease. The projected 5-year relapse-free survival (RFS) and overall survival (OS) of group I were 86.69% (95% CI, 57.9 - 
97.7%) and 90.0% (95% CI, 58.0 - 97.8%), respectively. And the projected 5-year relapse-free survival RFS and OS of 
group II were 86.67% (95% CI, 57.0 - 88.2%) and 93.33% (95% CI, 73.3 - 98.7%) respectively. There were no statistically 
significant differences in RFS (P = 0.485) and OS (P = 0.551) between the two groups.
Conclusion: Our data suggest that chemotherapy alone may be a reasonable alternative treatment for stage I/II gastric 
large-cell lymphoma but this result must be confirmed by prospective randomized clinical trials.
Introduction
Surgery has been the conventional treatment for patients
with localized gastric lymphoma [1,2]. Adjuvant chemo-
therapy or radiotherapy was often used for patients with
regional lymph node involvement. Systemic chemother-
apy has been the treatment of choice for most nodal and
extra nodal lymphomas as reported in published data
which support the safety and efficacy of conservative
treatments in the case of stage I/II primary gastric large-
cell B lymphoma (PGDLCL). As the primary chemother-
apy treatment was given either alone or followed by radi-
ation therapy, the role of surgical resection of the primary
tumor needs to be clearly defined and justified [3-5]. This
retrospective study investigated the clinical outcome of
localized gastric lymphoma treated by chemotherapy
alone or surgery followed by chemotherapy.
Methods
Patients
All records of patients which were diagnosed as having
gastric lymphoma during the period 1999 and 2006, were
reviewed and patients fulfilling the following criteria
were included in this study: histological proven large-cell
B lymphoma of the stomach; complete clinical informa-
tion for stage I/II disease (Musshoff modification of Ann
Arbor system); patients who received curative surgery
followed by adjuvant anthracycline based chemotherapy
(group I) or chemotherapy alone with anthracycline-con-
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taining regimens (group II), primary management and
follow up in our institution. Patients with mucosa associ-
ated lymphoid tissue (MALT) lymphoma were excluded.
Clinical evaluation
Staging procedures included complete physical examina-
tions, inspection for waldeyer's ring, complete blood cell
count and differential count, blood chemistry, upper gas-
trointestinal endoscopy, chest and abdomen CT scan,
bone marrow aspiration and biopsy. The staging was
determined according to the Musshoff modification of
Ann Arbor system [6] which divided stage II disease into
stage IIE1 and stage IIE2. In stage IE the tumor remains
confined within the stomach; in stage IIE1 the perigastric
nodal involvement was positif; in stage IIE2 more distant
nodal involvement was found up to the region below the
diaphragm. Grading of treatment toxicity as well as
tumor response was evaluated according to the criteria
defined by the World Health Organization [7]. Response
to chemotherapy was evaluated by physical examination,
endoscopy, and image studies every 3 cycle of chemother-
apy. Complete response (CR) was defined as the disap-
pearance of all evidence of tumor(s) for a duration of at
least 4 weeks. Partial response (PR) was defined as > 50%
reduction in the sum of the products of the longest per-
pendicular diameters of all measurable lesions in radio-
graphic images, with the reduction lasting at least 4
weeks. Stable disease (SD) was defined as < 50% reduc-
tion or < 25% increase in the sum of the products of the
longest perpendicular diameters of all measurable
lesions, lasting > 4 weeks. Patients with progressive
lesions were not classified as having PR or SD. Progres-
sive disease (PD) was defined as the appearance of new
lesions or > 25% increase in the area(s) of original mea-
surable disease.
Statistical analysis (SPSS16.0)
Comparisons between clinical and pathological features
were done by Pearson chi-square test. Overall survival
was calculated from the date of diagnosis to the date of
last follow-up or death from any cause. Relapse-free sur-
vival was calculated from the date of surgery for group I
or complete remission for group II to the date of tumor
relapse defined by the results of imaging studies or endo-
scopic biopsy. Survival distribution of relapse free sur-
vival and overall survival were plotted by the estimating
method of Kaplan and Meier [8]. Different survival
curves were compared with the log-rank test. All p values
were two-tailed and a p value < 0.05 was considered to be
statistically significant. SPSS version 16.0 was used for all
statistical analyses.
Consent and statement of ethical approval
As the treatment of each patient was decided by the med-
ical staff of the centre, oral consent was obtained from the
subjects and was approved by the institutional review
boards of the National Institute of Oncology, Cancer
Centre in Rabat
This study was approved by the institutional review
boards of National Institute of Oncology, in Rabat.
Results
Patients Characteristics
Patients' characteristics are summarized in table 1.
Eighty-two patients who fulfilled the broad-spectrum
diagnostic criteria for PGL, excluding those with MALT
lymphoma, were identified. Among 82 patients, 52 who
received chemotherapy alone were categorized into the
group II and the other 30 who received total gastrectomy
followed by chemotherapy were categorized into group I.
Clinico-pathological features of the patients are listed in
table 1. No significant difference was noted for all other
major characteristics between these two groups. Group II
had significantly more localized disease with fewer
patients in stage II-2 (p = 0.023). All patients received
Anti-ulcer therapy during chemotherapy.
Response to Treatment
All patients received CHOP (cyclophosphamide, doxoru-
bicin, vincristine, prednisone) chemotherapy regimen
which consisted of intravenous injection of cyclophosph-
amide 750 mg/m², doxorubicin 50 mg/m², and vincristine
1.4 mg/m² (maximum 2 mg) on day 1, and prednisone 60
mg/m2 orally on days 1-5. The median number of cycles
of chemotherapy was 4 (range: from 1 to 6) for group I,
and 5 (range: from 3 to 8) for group II. For group I, thir-
teen patients underwent total gastrectomy with curative
intent before chemotherapy. Among those patients we
evaluated the response to chemotherapy alone in group II
in which complete response was achieved in 87% (45/52),
partial responses in 6% and progression disease in 7%.
Salvage gastrectomy was undergone for five patients:
three had gastric perforation and two had upper gastroin-
testinal bleeding.
Outcome of the patients
Only one local relapse occurred in chemotherapy group
II and the others relapses in the 2 groups were dissemi-
nated. The projected 5-year RFS and OS of group I were
86.69% (95% CI, 57.9 - 97. 7%) and 90.0% (95% CI, 58.0 -
97.8%) respectively. The projected 5-year relapse-free
survival (RFS) and overall survival (OS) were 86.67% (95%
CI, 57.0 - 88.2%) and 93.33% (95% CI, 73.3-98.7%) respec-
tively in group II. There were no statistically significant
differences in RFS (P = 0.485) and OS (P = 0.551) between
the two groups (figure 1 and 2).
Treatment-Related Toxicities
The treatment-related toxicities are summarized in table
2. There were no treatment-related deaths. Grade 3/4 leu-Sbitti et al. Journal of Hematology & Oncology 2010, 3:23
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Table 1: Characteristics of patients with localized and advanced primary gastric lymphoma treated with surgery followed 
by chemotherapy or chemotherapy alone
Parameters Surgery plus chemotherapy
Group I
(n = 30) (%)
Chemotherapy
Group II
(n = 52) (%)
P value
Age years 52 53
Range 19-79 19-81
Sexe
Male 25 (83%) 33 (64%) P = 0.057
Female 5 (17%) 19 (36%)
Musshoff
Staging
I 26 (86%) 32 (61%) P = 0.023
II-1 3 (10%) 6 (12%)
II-2 1 (4%) 14 (27%)
Figure 1 Relapse-free survival of localized primary gastric lymphoma.Sbitti et al. Journal of Hematology & Oncology 2010, 3:23
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kopenia was the most side effects for group II. Adjuvant
chemotherapy for group I result in similar incidence of
haematological toxicity. After administration of chemo-
therapy in group II, three patients (one patient after first
cycle and two after two cycles) developed gastric perfora-
tion and two patients (after first cycle) gastrointestinal
bleeding. Both of these complications were successfully
managed by surgical emergency repair. All these patients
presented with stage II-2 disease, with performance sta-
tus (PS) 2/3, and older age 72 years (range: 67-81 years).
They died of distance disease progression after 6, 13 and
18 months after diagnosis respectively. Anastomosis leak-
age was noted in two patients in group I. They had poor
PS (3/4), weight loss (20%) and dismal nutritional status.
They died after septic choc.
Discussion
This retrospective study suggests that the clinical out-
come of localized PGL treated by chemotherapy alone is
comparable to that treated by surgery combined with
chemotherapy in terms of disease-free survival and over-
all survival, so surgery is not required. Review of the liter-
ature showed that most of the relevant studies of
treatment and outcome of PGL, considered small num-
bers of patients and were conducted retrospectively
[9,10]. The optimal treatment for localized PGL remains
to be established. Earlier studies claimed that surgery was
the first-line treatment of choice for patients with local-
ized gastric lymphoma [11,12]. Advocates for primary
surgery included that patients who underwent surgery
had a better survival than those who did not, and surgery
might reduce the risk of bleeding or perforation during
chemotherapy or radiotherapy. However because the suc-
cess of surgical management of PGL depends on tumor
size, the depth of its penetration into gastric tissue, and
the involvement of regional lymph nodes [13-15] some
investigators began using chemotherapy, mostly CHOP
and its related regimens, to control the tumors and pre-
vent postoperative morbidity gastrectomy [9,16,17].
Recently the roles of stomach-conserving therapies for
localized PGL have been emphasized. Relatively little
data, however, exist for chemotherapy as sole treatment
modality in localised gastric DLBCL, which nevertheless
are highly promising and suggest that combination ther-
Figure 2 Overall survival of localized primary gastric lymphoma.Sbitti et al. Journal of Hematology & Oncology 2010, 3:23
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apy might over treat a substantial proportion of patients
[3,5]. Maor and al showed that the 6-year overall survival
of patients treated with chemotherapy alone was 76%
[17]. However, for bulky tumors, the advantage of chemo-
therapy is overshadowed by the potential for tumor
bleeding and gastric perforation. Most studies have
revealed a rather low incidence of severe haemorrhage or
perforation, accounting for 2.1% and 1.7%, respectively, of
those individuals treated with chemotherapy alone, and
2.2% and 0.9%, respectively, of surgically-treated individ-
uals [17,18]. Such evidence suggests that the role of sur-
gery in the treatment of PGL may be less important than
previously considered. In our study, gastric perforation
and gastric bleeding developed respectively in 3 patients
and 2 patients receiving primary chemotherapy and thus
this remains a real and noteworthy complication. To
avoid such severe complications, we recommend re-eval-
uating patients by endoscopy after two cycles of chemo-
therapy. At the same time, patients should be warned that
complications such as gastric perforation and bleeding
are possible, and awareness programs involving compre-
hensive education should be part of the treatment pro-
cess [19]. Our study has provided good evidence in
support of chemotherapy alone. The best management of
PGL has yet not been established and the choice of treat-
ment modality is mainly dependent on the expertise of
the primary responsible specialists. Oncologists pre-
ferred systemic chemotherapy alone and reserved surgery
as salvage treatment, while surgeons preferred curative
resection followed by adjuvant chemotherapy [20]. Such
variation in patient selection has made comparison
among different studies difficult. Prospective studies are
needed to evaluate each strategy in terms of both survival
and treatment-related complications. Our data suggest
that systemic chemotherapy alone may be a reasonable
alternative treatment for stage I/II large-cell lymphoma of
the stomach. We may presume, however, that organ func-
tion is better preserved by chemotherapy alone than sur-
gery. Resection of the primary tumor before systemic
chemotherapy does not appear to improve the cure rate
of this group of patients and could be reserved for those
with severe complication (severe bleeding or perforation)
after chemotherapy but this result must be confirmed in
prospective randomized clinical trial including monoclo-
nal antibody.
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Table 2: Treatment-related complications of primary gastric lymphoma
Group I Group II
Toxicity Nb % Nb %
Leucopoeniae (G3/4) 5 15 10 18
Thrombocytopeniae (G3/4) 1 0.3 0 0
Fever 2 0.6 3 0.5
UGI Bleeding NA NA 2 0.3
Anastomosis leakage 2 0.03 NA NA
Gastric obstruction NA NA 1 1.9%
perforation NA NA 3 5.7%
Abbreviations. G: grade; UGI: upper gastrointestinal; NA: not applicableSbitti et al. Journal of Hematology & Oncology 2010, 3:23
http://www.jhoonline.org/content/3/1/23
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